Shaalan, U., Sharawy, A., Othman, M., Elharoun, H. (2017). Evaluation of Testing of Serum Survivin and Alpha Fetoprotein in Patients with Hepatocellular Carcinoma and Hepatitis C Viral Infection. Research Journal of Applied Biotechnology, 3(2), 37-50. doi: 10.21608/rjab.2017.104787
Usama Shaalan; Ahmed Sharawy; Mohamad Othman; Hani Elharoun. "Evaluation of Testing of Serum Survivin and Alpha Fetoprotein in Patients with Hepatocellular Carcinoma and Hepatitis C Viral Infection". Research Journal of Applied Biotechnology, 3, 2, 2017, 37-50. doi: 10.21608/rjab.2017.104787
Shaalan, U., Sharawy, A., Othman, M., Elharoun, H. (2017). 'Evaluation of Testing of Serum Survivin and Alpha Fetoprotein in Patients with Hepatocellular Carcinoma and Hepatitis C Viral Infection', Research Journal of Applied Biotechnology, 3(2), pp. 37-50. doi: 10.21608/rjab.2017.104787
Shaalan, U., Sharawy, A., Othman, M., Elharoun, H. Evaluation of Testing of Serum Survivin and Alpha Fetoprotein in Patients with Hepatocellular Carcinoma and Hepatitis C Viral Infection. Research Journal of Applied Biotechnology, 2017; 3(2): 37-50. doi: 10.21608/rjab.2017.104787
Evaluation of Testing of Serum Survivin and Alpha Fetoprotein in Patients with Hepatocellular Carcinoma and Hepatitis C Viral Infection
1Molecular diagnostics and Therapeutics department, Genetic engineering and biotechnology research institute, university of Sadat city, Sadat city, Egypt
2Clinical Pathology Department, National Liver Institute, Menofia University
3Bioinformatic department, Genetic Engineering and Biotechnology research institute, university of Sadat city, Sadat city, Egypt
Abstract
Survivin is specific antiapoptotic gene product expressed in a variety of human neoplasmswhose overexpression might assist in early diagnosis and as a prognostic marker. Objectives: The aim was to evaluate the plasma levels of survivin and alpha fetoprotein in patients with chronic hepatitis C viral infection (HCV) with and without hepatocellular carcinoma (HCC). Subjects : 70 subjects were divided into: a control group (Group I) ( 20 healthy volunteers ) and two patients groups: Group II, HCV group (20 patients); and Group III, HCC with HCV(30 patients ). Methods: Thorough physical examination, ultrasonography of the abdomen, laboratory investigations (liver profile, anti-HCV antibodies, hepatitis B surface antigen, Alpha fetoprotein (chemiluminometry) and Survivin (ELISA)) were performed. Results: There was a significant increase in survivin level in HCV patients (Group II) when compared to the control group (p=0.039), along with a significant increase in AFP in Groups II and III when compared to Group I (P<0.001 for both). AFP also distinguished between the two HCV groups. The best generated cut off value for AFP was 10.9 ng/ml and for survivin 13.7 pg/ml. Serum survivin diagnostic sensitivity was 53.3%, diagnostic specificity 62.5% and efficiency 58.6%, in contrast to 100%, 92.5% and 95.7%, respectively, for AFP. Conclusions: While survivin showed significant increase in the HCV group, its diagnostic performance was lower and it proved to be less reliable as a tumor marker for HCC than did AFP.
View on SCiNiTO
Top